WuXi Biologics (药明生物; WuXi Biologics (Cayman) Inc.) is a global contract research, development, and manufacturing organization (CRDMO) focused on biopharmaceuticals. The company provides end-to-end services covering cell line development, process and analytical development, technology transfer, and GMP manufacturing of drug substance and drug product, including sterile fill–finish for vials and pre-filled syringes. Its platforms support monoclonal antibodies and other recombinant protein therapeutics.
Headquartered in Wuxi, China and listed in Hong Kong, WuXi Biologics operates a network of GMP facilities across Asia, Europe, and North America, utilizing single-use and perfusion bioreactor technologies. The company applies Quality by Design principles, process analytical technologies, and integrated digital systems to enable scale-up and lifecycle management. WuXi Biologics serves global biopharmaceutical customers under multi-site quality systems with regulatory approvals from major health authorities such as the FDA, EMA, and China’s NMPA.
To provide comprehensive coverage, we aggregate data and news under the name WuXi, encompassing the following company names, divisions, and related entities:
WuXi Biologics (Cayman) Inc. and 药明生物.
This list encompasses current and former names, alternate names, and key divisions associated with WuXi, ensuring you can easily find all relevant information under a single, unified profile.
